Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disorder affecting 30% of psoriatic patients. Effective treatment, especially with biologics like IL-17 and TNF inhibitors, is vital for improving patient...
Read MorePsoriatic arthritis (PsA) is a chronic, autoimmune form of arthritis that is associated with a substantial humanistic and economic burden. Potential differences in patient-reported outcomes (PROs) and economic outcomes among...
Read More
PsA and AD can coexist, and the presence of both conditions may mean special attention should be given to selecting optimal treatment.
Read More
Risk factors for patients with psoriasis developing psoriatic arthritis, and potential pharmacological and non-pharmacological interventions.
Read More
What is the current state of biological therapies for psoriatic arthritis, and what does the future of biological therapy for psoriatic arthritis hold?
Read More
MONDAY, July 29, 2024 (HealthDay News) — Psoriasis and psoriatic arthritis may be associated...
Read More
The study concluded that BASDAI and ASDAS are effective tools for evaluating axial disease activity in PsA
Read More
MONDAY, July 1, 2024 (HealthDay News) — Psoriasis is associated with fatigue, especially...
Read More
Patients with active psoriatic arthritis have shown significant efficacy results with izokibep.
Read More
PRO-SPIRIT study examines the real-world efficacy results of disease-modifying antirheumatic drugs for patients with psoriatic arthritis.
Read More
With new research, medical professionals are even closer to implementing personalized medicine in care for patients with psoriatic arthritis.
Read More
The following is a summary of “Vaccination recommendations for adults receiving biologics...
Read More
The following is a summary of “Vaccination recommendations for adults receiving biologics...
Read More
Psoriatic arthritis (PsA) and atopic dermatitis (AD) can coexist, and the presence of both...
Read MoreIL-23 inhibitors were recently approved for the treatment of skin psoriasis and psoriatic arthritis (PsA). Risankizumab, a humanized monoclonal antibody that specifically binds the p19 subunit of IL-23, has proven effective on...
Read More
Disease duration and disease activity were significant predictors of cardiovascular risk in PsA patients.
Read MoreLipid pathways play a crucial role in psoriatic arthritis development, and some lipid-lowering drugs are believed to have therapeutic benefits due to their anti-inflammatory properties. Traditional observational studies face...
Read MoreTo assess the frequency of simultaneous distal interphalangeal (DIP) joint disease and adjacent nail psoriasis (finger unit) among patients with psoriatic arthritis (PsA) and compare the efficacy of the interleukin (IL)-17A...
Read More
The following is a summary of “Use of the Bath Ankylosing Spondylitis Disease Activity Index...
Read MoreJuvenile psoriatic arthritis (JPsA) is a heterogeneous type of non-systemic chronic inflammatory arthritis affecting children and young people. This review focuses on highlighting challenges in harmonising recommendations for...
Read More
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
